Aigen Investment Management LP Acquires Shares of 16,839 Exelixis, Inc. $EXEL

Aigen Investment Management LP acquired a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) in the 4th quarter, HoldingsChannel reports. The institutional investor acquired 16,839 shares of the biotechnology company’s stock, valued at approximately $738,000.

A number of other large investors have also recently made changes to their positions in EXEL. Anchor Investment Management LLC boosted its holdings in shares of Exelixis by 500.0% in the third quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 500 shares during the period. Acumen Wealth Advisors LLC purchased a new stake in shares of Exelixis in the fourth quarter worth $29,000. Activest Wealth Management purchased a new stake in shares of Exelixis in the fourth quarter worth $32,000. Northwestern Mutual Wealth Management Co. raised its position in shares of Exelixis by 1,380.4% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock worth $34,000 after buying an additional 773 shares in the last quarter. Finally, V Square Quantitative Management LLC purchased a new stake in shares of Exelixis in the fourth quarter worth $44,000. 85.27% of the stock is owned by institutional investors.

Exelixis Stock Performance

EXEL stock opened at $53.13 on Monday. Exelixis, Inc. has a 52-week low of $33.76 and a 52-week high of $53.93. The firm has a market capitalization of $13.35 billion, a price-to-earnings ratio of 17.65, a PEG ratio of 1.53 and a beta of 0.41. The firm has a 50 day moving average price of $47.98 and a 200-day moving average price of $44.91.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.12. The business had revenue of $610.81 million during the quarter, compared to analyst estimates of $607.51 million. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The company’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.55 EPS. As a group, sell-side analysts forecast that Exelixis, Inc. will post 3.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Wall Street Zen upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Zacks Research downgraded Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 5th. Royal Bank Of Canada reduced their price objective on Exelixis from $46.00 to $43.00 and set a “sector perform” rating on the stock in a research note on Monday, March 2nd. TD Cowen raised their price objective on Exelixis from $51.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Exelixis in a research note on Tuesday, May 19th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Exelixis has a consensus rating of “Hold” and an average price target of $47.35.

Insider Activity

In related news, CFO Christopher J. Senner sold 34,901 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $50.00, for a total value of $1,745,050.00. Following the completion of the transaction, the chief financial officer owned 952,317 shares of the company’s stock, valued at approximately $47,615,850. This represents a 3.54% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Sue Gail Eckhardt sold 9,812 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $50.14, for a total transaction of $491,973.68. Following the completion of the sale, the director owned 16,079 shares in the company, valued at approximately $806,201.06. The trade was a 37.90% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 219,170 shares of company stock worth $10,620,641. Company insiders own 2.60% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.